Cargando…

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma

TRAIL (TNF-related apoptosis-inducing ligand) and its derivatives are potentials for anticancer therapy due to the selective induction of apoptosis in tumor cells upon binding to death receptors DR4 or DR5. Previously, we generated a DR5-selective TRAIL mutant variant DR5-B overcoming receptor-depen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yagolovich, Anne V., Isakova, Alina A., Artykov, Artem A., Vorontsova, Yekaterina V., Mazur, Diana V., Antipova, Nadezhda V., Pavlyukov, Marat S., Shakhparonov, Mikhail I., Gileva, Anastasia M., Markvicheva, Elena A., Plotnikova, Ekaterina A., Pankratov, Andrey A., Kirpichnikov, Mikhail P., Gasparian, Marine E., Dolgikh, Dmitry A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604365/ https://www.ncbi.nlm.nih.gov/pubmed/36293545 http://dx.doi.org/10.3390/ijms232012687

Ejemplares similares

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH–DR5-B with Dual VEGFR2 and DR5 Receptor Specificity
por: Yagolovich, Anne V., et al.
Publicado: (2022)

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells
por: Yagolovich, Anne, et al.
Publicado: (2021)

Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
por: Yagolovich, Anne V., et al.
Publicado: (2020)

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2021)

Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2022)

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells
por: Gileva, Anastasia, et al.
Publicado: (2023)

Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4
por: Bychkov, Maxim L., et al.
Publicado: (2014)

Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B More Efficiently Than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors
por: Artykov, Artem A., et al.
Publicado: (2020)

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway
por: Yagolovich, Anne V., et al.
Publicado: (2023)

Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
por: Fadeev, Roman, et al.
Publicado: (2019)

The Role of Non-coding RNAs in the Pathogenesis of Glial Tumors
por: Kovalenko, T. F., et al.
Publicado: (2021)

An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy
por: Ai, Shichao, et al.
Publicado: (2018)

MicroRNA-539-5p-Loaded PLGA Nanoparticles Grafted with iRGD as a Targeting Treatment for Choroidal Neovascularization
por: Alanazi, Jouri S., et al.
Publicado: (2022)

iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome
por: Pooladanda, Venkatesh, et al.
Publicado: (2021)

An iRGD Based Strategy to Study Electrochemically the Species Inside a Cell
por: Ning, Limin, et al.
Publicado: (2012)

Identification of Novel Interaction Partners of AIF Protein on the Outer Mitochondrial Membrane
por: Fadeeva, N. P., et al.
Publicado: (2018)

Enhanced Therapeutic Efficacy of iRGD-Conjugated Crosslinked Multilayer Liposomes for Drug Delivery
por: Liu, Yarong, et al.
Publicado: (2013)

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017)

iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
por: Kang, Sujin, et al.
Publicado: (2020)

Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma
por: Egorova, Anna, et al.
Publicado: (2021)

Dual Effect of Chemo-PDT with Tumor Targeting Nanoparticles Containing iRGD Peptide
por: Kim, Gye Lim, et al.
Publicado: (2023)

Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy
por: Yaghoubi, Atieh, et al.
Publicado: (2023)

iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis
por: Egorova, Anna, et al.
Publicado: (2023)

Expression and Intracellular Localization of Paraoxonase 2 in Different Types of Malignancies
por: Shakhparonov, M. I., et al.
Publicado: (2018)

Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide
por: E. M. Eid, Eltayeb, et al.
Publicado: (2019)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy
por: Chen, Jiejian, et al.
Publicado: (2019)

Molecular Imaging of Steroid-Induced Osteonecrosis of the Femoral Head through iRGD-Targeted Microbubbles
por: Zhao, Ping, et al.
Publicado: (2022)

iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma
por: Dong, Yanbing, et al.
Publicado: (2023)

Molecular View on the iRGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles
por: D’Amore, Vincenzo Maria, et al.
Publicado: (2023)

Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2
por: Antipova, Nadezhda V., et al.
Publicado: (2020)

Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability
por: Hu, Cuihua, et al.
Publicado: (2018)

iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers
por: Zuo, Houdong
Publicado: (2019)

Combined Self-Assembled iRGD Polymersomes for Effective Targeted siRNA Anti-Tumor Therapy
por: Li, Dongying, et al.
Publicado: (2022)

Correction: iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma
por: Dong, Yanbing, et al.
Publicado: (2023)

The Antitumour Activity of a Curcumin and Piperine Loaded iRGD-Modified Liposome: In Vitro and In Vivo Evaluation
por: Wang, Yingzheng, et al.
Publicado: (2023)

Molecular Interactions between Neuroglobin and Cytochrome c: Possible Mechanisms of Antiapoptotic Defense in Neuronal Cells
por: Semenova, Marina A., et al.
Publicado: (2023)

Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus
por: Al-Zaher, Ahmed Abdullah, et al.
Publicado: (2018)

Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma
por: Zhou, Chong, et al.
Publicado: (2022)

iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity
por: Diaz Bessone, María Inés, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l7ibqlklomdto4qft09c0i02mn